Clinical Trial Update: Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT [Phase 3]

View source ↗

Summary

A Phase 3 multicenter randomized trial compares segmentectomy versus lobectomy for 2–3 cm IASLC Grade 1–2 lung adenocarcinoma; recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING